Asenapine: A novel psychopharmacologic agent with a unique human receptor signature

Journal of Psychopharmacology

Volumn 23, Issue 1, 2009, Pages 65-73

  Shahid, M ^a   Walker, G B ^a   Zorn, S H ^b   Wong, E H F ^b  

^a Schering Plough Research Institute   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Affinity; Asenapine; Bipolar disorder; Human receptor; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ASENAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; BIPOLAR DISORDER; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR AFFINITY; SCHIZOPHRENIA;

BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; CLONING, MOLECULAR; CLOZAPINE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HISTAMINE RELEASE; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PSYCHOTROPIC DRUGS; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SUBSTRATE SPECIFICITY;

EID: 58649100010     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082944     Document Type: Article

References (44)

1. Arnt J., Skarsfeldt T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101
2. Blin O. (1999) A comparative review of new antipsychotics. Can J Psychiatry 44: 235-44
3. Caldirola P.M., Svartengren J. (2005) Selective serotonin 5-HT6 receptor antagonist(s) for the treatment of obesity [abstract]. Neuropsychopharmacology 30: S54
4. Cheng Y., Prusoff W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-108
5. Davis J.M., Chen N., Glick I.D. (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-64
6. De Boer T., Berendsen H., Broekkamp C L E, Vrijmoed-de Vries M.C., Vos R M E, Tonnaer J A D M (1993) Org-5222. Drugs Future 18: 1117-23
7. Dean B., Scarr E. (2004) Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord 3: 217-25
8. Geddes J., Freemantle N., Harrison P., Bebbington P. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321: 1371-6
9. Giorgetti M., Tecott L.H. (2004) Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 488: 1-9
10. Guscott M.R., Egan E., Cook G.P., Stanton J.A., Beer M.S., Rosahl T.W., Hartmann S., Kulagowski J., McAllister G., Fone K.C., Hutson P.H. (2005) Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 48: 492-502
11. Hedlund P.B., Sutcliffe J.G. (2004) Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25: 481-6
12. Holthausen E.A., Wiersma D., Cahn W., Kahn R.S., Dingemans P.M., Schene A.H., van den Bosch R.J. (2007) Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res 149: 71-80
13. Horowski R., Jahnichen S., Pertz H.H. (2004) Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19: 1523-4
14. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., Gibbs E.M., Zawalich W.S., Rollema H. (2005) Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54: 1552-8
15. Joyce J.N., Millan M.J. (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10: 917-25
16. Lane H.Y., Lee C.C., Liu Y.C., Chang W.H. (2005) Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6: 139-49
17. Leriche L., Diaz J., Sokoloff P. (2004) Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor. Neurotox Res 6: 63-71
18. Lieberman J.A., Mailman R.B., Duncan G., Sikich L., Chakos M., Nichols D.E., Kraus J.E. (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44: 1099-117
19. Lindenmayer J.P., Khan A. (2004) Pharmacological treatment strategies for schizophrenia. Expert Rev Neurother 4: 705-23
20. Marcus M.M., Jardemark K.E., Wadenberg M.L., Langlois X., Hertel P., Svensson T.H. (2005) Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8: 315-27
21. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-72
22. Moller H.J. (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17: 793-823
23. Moller H.J., Bottlender R., Wegner U., Wittmann J., Strauss A. (2000) Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatr Scand Suppl. 407: 54-7
24. Neale A.C., Jenkins H., Amend D., Lesem M. (2005) A 14 day, dose escalation, double blind, randomized, placebo-controlled study of SB518 in adult patients with schizophrenia [abstract]. Neuropsychopharmacology 30: S54
25. Nemeroff C.B. (2003) Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 64: 532-9
26. Newcomer J.W. (2004) Metabolic risk during antipsychotic treatment. Clin Ther 26: 1936-46
27. Potkin S.G., Alva G., Panagides J., Carreon D.T., Långström B., Mukherjee J., de Greef R. (2003) Predicting clinical antipsychotic doses from preclinical and PET studies: a case study with asenapine. Presented at the American College of Neuropsychopharmacology 42nd Annual Meeting, San Juan, Puerto Rico, 7-11 December
28. Potkin S.G., Cohen M., Panagides J. (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 68: 1492-1500
29. Remington G. (2003) Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci 28: 275-84
30. Reynolds G.P., Yao Z., Zhang X., Sun J., Zhang Z. (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15: 142-51
31. Richelson E., Souder T. (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29-39
32. Roth B.L., Hanizavareh S.M., Blum A.E. (2004 a) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 174: 17-24
33. Roth B.L., Sheffler D.J., Kroeze W.K. (2004 b) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-9
34. Roth B.L., Sheffler D.J., Potkin S.G. (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res 3: 108-17
35. Rowley M., Bristow L.J., Hutson P.H. (2001) Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 44: 477-501
36. Schwartz J.C., Diaz J., Pilon C., Sokoloff P. (2000) Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 31: 277-87
37. Seeman P. (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47: 27-38
38. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-11
39. Stahl S.M. (2003) Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Companion J Clin Psychiatry 5: 9-13
40. Stip E. (2006) Cognition, schizophrenia and the effect of antipsychotics. Encephale 32: 341-50
41. Svensson T.H. (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1145-58
42. Svirskis T., Korkeila J., Heinimaa M., Huttunen J., Ilonen T., Ristkari T., Hietala J., Syvalahti E., McGlashan T., Vahlberg T., Salokangas R.K. (2007) Quality of life and functioning ability in subjects vulnerable to psychosis. Compr Psychiatry 48: 155-60
43. Thomas D.R., Hagan J.J. (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3: 81-90
44. Woolley M.L., Marsden C.A., Fone K.C. (2004) 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 3: 59-79